Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new member of the Coronaviridae family responsible for the coronavirus disease 19 (COVID-19) pandemic. To date, SARS-CoV-2 has been accountable for over 624 million infection cases and more than 6.5 million human deaths. The development and implementation of SARS-CoV-2 reverse genetics approaches have allowed researchers to genetically engineer infectious recombinant (r)SARS-CoV-2 to answer important questions in the biology of SARS-CoV-2 infection. Reverse genetics techniques have also facilitated the generation of rSARS-CoV-2 expressing reporter genes to expedite the identification of compounds with antiviral activity in vivo and in vitro. Likewise, reverse genetics has been used to generate attenuated forms of the virus for their potential implementation as live-attenuated vaccines (LAV) for the prevention of SARS-CoV-2 infection. Here we describe the experimental procedures for the generation of rSARS-CoV-2 using a well-established and robust bacterial artificial chromosome (BAC)-based reverse genetics system. The protocol allows to produce wild-type and mutant rSARS-CoV-2 that can be used to understand the contribution of viral proteins and/or amino acid residues in viral replication and transcription, pathogenesis and transmission, and interaction with cellular host factors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Andersen KG et al (2020) The proximal origin of SARS-CoV-2. Nat Med 26(4):450–452
Lu R et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224):565–574
Ksiazek TG et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348(20):1953–1966
Peiris JS et al (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361(9366):1319–1325
van Boheemen S et al (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3(6):e00473
Zaki AM et al (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814–1820
Alfaraj SH et al (2019) Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: a cohort study. Travel Med Infect Dis 29:48–50
Gudbjartsson DF et al (2020) Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med 382(24):2302–2315
Petersen E et al (2020) Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dise 20(9):e238–e244
Sikkema RS et al (2019) Global status of Middle East respiratory syndrome coronavirus in dromedary camels: a systematic review – CORRIGENDUM. Epidemiol Infect 147:e198
Sarkar M, Madabhavi I (2022) SARS-CoV-2 variants of concern: a review. Monaldi Arch Chest Dis 93(3):2337
Ahmad A, Fawaz MAM, Aisha A (2022) A comparative overview of SARS-CoV-2 and its variants of concern. Infez Med 30(3):328–343
Ashoor D et al (2022) How concerning is a SARS-CoV-2 variant of concern? Computational predictions and the variants labeling system. Front Cell Infect Microbiol 12:868205
Bian L et al (2022) Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. Hum Vaccin Immunother 18(5):2057161
Mohapatra RK et al (2022) SARS-CoV-2 and its variants of concern including Omicron: a never ending pandemic. Chem Biol Drug Des 99(5):769–788
Rabaan AA et al (2022) A comprehensive review on the current vaccines and their efficacies to combat SARS-CoV-2 variants. Vaccines (Basel) 10(10):1655
Khare S et al (2022) SARS-CoV-2 vaccines: types, working principle, and its impact on thrombosis and gastrointestinal disorders. Appl Biochem Biotechnol 195:1541–1573
Liang HY et al (2022) SARS-CoV-2 variants, current vaccines and therapeutic implications for COVID-19. Vaccines (Basel) 10(9)
Mahmood A et al (2022) Acute adverse effects of vaccines against SARS-COV-2. Cureus 14(7):e27379
Park H et al (2022) Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. J Microbiol 60(3):308–320
Sendi P et al (2022) First-generation oral antivirals against SARS-CoV-2. Clin Microbiol Infect 28(9):1230–1235
Moreno S et al (2022) Use of antivirals in SARS-CoV-2 infection critical review of the role of remdesivir. Drug Des Devel Ther 16:827–841
Nappi F, Iervolino A, Avtaar Singh SS (2022) Molecular insights of SARS-CoV-2 antivirals administration: a balance between safety profiles and impact on cardiovascular phenotypes. Biomedicine 10(2):437
Mabrouk MT et al (2022) Advanced materials for SARS-CoV-2 vaccines. Adv Mater 34(12):e2107781
Wu F et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579(7798):265–269
Almazan F et al (2014) Coronavirus reverse genetic systems: infectious clones and replicons. Virus Res 189:262–270
Enjuanes L et al (2006) Biochemical aspects of coronavirus replication and virus-host interaction. Annu Rev Microbiol 60:211–230
Zhu N et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733
Nogales A et al (2022) Mutation L319Q in the PB1 polymerase subunit improves attenuation of a candidate live-attenuated influenza a virus vaccine. Microbiol Spectr 10(3):e0007822
Ye C et al (2020) Rescue of SARS-CoV-2 from a single bacterial artificial chromosome. MBio 11(5):e02168–e02120
Marquez-Jurado S et al (2018) An alanine-to-valine substitution in the residue 175 of zika virus NS2A protein affects viral RNA synthesis and attenuates the virus in vivo. Viruses 10(10)
Jangra S, et al (2021) The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv, 2021
Nogales A et al (2017) The K186E amino acid substitution in the canine influenza virus H3N8 NS1 protein restores its ability to inhibit host gene expression. J Virol 91(22):e00877-17
Perez DR et al (2017) Plasmid-based reverse genetics of influenza a virus. Methods Mol Biol 1602:251–273
Nogales A et al (2016) Development and applications of single-cycle infectious influenza a virus (sciIAV). Virus Res 216:26–40
Kehrer T, et al (2022) Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis. bioRxiv, 2022
Veleanu A et al (2022) Molecular analyses of clinical isolates and recombinant SARS-CoV-2 carrying B.1 and B.1.617.2 spike mutations suggest a potential role of non-spike mutations in infection kinetics. Viruses 14(9):2017
Chiem K et al (2022) Monitoring SARS-CoV-2 infection using a double reporter-expressing virus. Microbiol Spectr 10(5):e0237922
Chiem K, Nogales A, Martinez-Sobrido L (2022) Generation, characterization, and applications of influenza a reporter viruses. Methods Mol Biol 2524:249–268
Ye C et al (2023) Immunization with recombinant accessory protein-deficient SARS-CoV-2 protects against lethal challenge and viral transmission. Microbiol Spectr 11(3):e00653-23
Martinez-Sobrido L, de la Torre JC (2016) Reporter-expressing, replicating-competent recombinant arenaviruses. Viruses 8(7):197
Breen M et al (2016) Replication-competent influenza a viruses expressing reporter genes. Viruses 8(7):179
Chiem K et al (2022) Identification of amino acid residues required for inhibition of host gene expression by influenza virus a/Viet Nam/1203/2004 H5N1 PA-X. J Virol 96(5):e0040821
Morales Vasquez D et al (2022) Bioluminescent and fluorescent reporter-expressing recombinant SARS-CoV-2. Methods Mol Biol 2524:235–248
Ye C, Martinez-Sobrido L (2022) Generation of bi-reporter-expressing tri-segmented arenavirus. Methods Mol Biol 2524:223–233
Chiem K et al (2021) Bi-reporter vaccinia virus for tracking viral infections in vitro and in vivo. Microbiol Spectr 9(3):e0160121
Morales Vasquez D et al (2021) Live imaging and quantification of viral infection in K18 hACE2 transgenic mice using reporter-expressing recombinant SARS-CoV-2. J Vis Exp 177:e63127
Ye C et al (2021) Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses. Proc Natl Acad Sci U S A 118(41) e2111593118
Chiem K et al (2021) Amino acid residues involved in inhibition of host gene expression by influenza A/Brevig Mission/1/1918 PA-X. Microorganisms 9(5):1109
Nogales A, DeDiego ML, Martinez-Sobrido L (2022) Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use. Front Cell Infect Microbiol 12:954811
Ye C, de la Torre JC, Martinez-Sobrido L (2020) Reverse genetics approaches for the development of mammarenavirus live-attenuated vaccines. Curr Opin Virol 44:66–72
Martinez-Sobrido L, DeDiego ML, Nogales A (2020) Reverse genetics approaches for the development of new vaccines against influenza A virus infections. Curr Opin Virol 44:26–34
Avila-Perez G et al (2020) In vivo rescue of recombinant Zika virus from an infectious cDNA clone and its implications in vaccine development. Sci Rep 10(1):512
Blanco-Lobo P et al (2019) Novel approaches for the development of live attenuated influenza vaccines. Viruses 11(2):190
Martinez-Sobrido L, de la Torre JC (2017) Development of recombinant arenavirus-based vaccines. Methods Mol Biol 1581:133–149
Nogales A et al (2016) Rearrangement of influenza virus spliced segments for the development of live-attenuated vaccines. J Virol 90(14):6291–6302
Nogales A et al (2017) Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines. Virology 500:1–10
Martinez-Sobrido L, de la Torre JC (2016) Novel strategies for development of hemorrhagic fever arenavirus live-attenuated vaccines. Expert Rev Vaccines 15(9):1113–1121
Baker SF, Nogales A, Martinez-Sobrido L (2015) Downregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines. Future Virol 10(6):715–730
Cheng BY et al (2015) Arenavirus genome rearrangement for the development of live attenuated vaccines. J Virol 89(14):7373–7384
Cheng BY et al (2015) Development of live-attenuated arenavirus vaccines based on codon deoptimization. J Virol 89(7):3523–3533
Zhang Y et al (2022) A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. Proc Natl Acad Sci U S A 119(33):e2201616119
Xie X et al (2021) Engineering SARS-CoV-2 using a reverse genetic system. Nat Protoc 16(3):1761–1784
Thi Nhu Thao T et al (2020) Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature 582(7813):561–565
Ye C et al (2020) Rescue of SARS-CoV-2 from a single bacterial artificial chromosome. MBio 11(5):e02168-20
Chiem K et al (2021) Generation and characterization of recombinant SARS-CoV-2 expressing reporter genes. J Virol 95(7):e02209–e02220
Chiem K, Ye C, Martinez-Sobrido L (2020) Generation of recombinant SARS-CoV-2 using a bacterial artificial chromosome. Curr Protoc Microbiol 59(1):e126
Almazán F et al (2006) Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. J Virol 80(21):10900–10906
Hotard AL et al (2012) A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434(1):129–136
Pu SY et al (2011) Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic bacterial promoter activity of virus genomes. J Virol 85(6):2927–2941
Chiem K et al (2021) A bifluorescent-based assay for the identification of neutralizing antibodies against SARS-CoV-2 variants of concern in vitro and in vivo. J Virol 95(22):e0112621
Almazan F et al (2015) Engineering infectious cDNAs of coronavirus as bacterial artificial chromosomes. Methods Mol Biol 1282:135–152
Almazan F et al (2013) Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 4(5):e00650-13
Avila-Perez G et al (2019) Rescue of recombinant zika virus from a bacterial artificial chromosome cDNA clone. J Vis Exp 148:59537
Acknowledgments
Research on SARS-CoV-2 in L.M-S laboratory was partially supported by grants W81XWH2110103 and W81XWH2110095 from the Department of Defense (DoD) Peer Reviewed Medical Research Program (PRMRP); 1R43AI165089-01, 1R01AI161363-01, and 1R01AI161175-01A1 from the National Institutes of Health (NIH); the Center for Research on Influenza Pathogenesis and Transmission (CRIPT), one of the National Institute of Allergy and Infectious Diseases (NIAID)-funded Centers of Excellence for Influenza Research and Response (CEIRR; contract # 75N93021C00014); the Antiviral Countermeasures Development Center (AC/DC) (1U19AI171403-01), the Center for Antiviral Medicines & Pandemic Preparedness (CAMPP) (1U19AI171443-01), and the QCRG Pandemic Response Program (1U19AI171110-01), three of the National Institutes of Health (NIH)-funded Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern; the San Antonio Partnership for Precision Therapeutics; and the San Antonio Medical Foundation. Research in L.M-S was also partially supported by NIH R01AI145332, R01AI142985, and R01AI141607 grants and by DoD W81XWH1910496 PRMRP grant.
Materials Availability
The pBeloBAC11-SARS-CoV-2 BAC clone described in this book chapter for the generation of rSARS-CoV-2 is available at this website: https://www.txbiomed.org/services-2/reverse-genetics-plasmids. Other BAC clones as well as their respective rSARS-CoV-2 are also available at the same website.
Conflict of Interest
C.Y, F.A, and L. M.-S are co-inventors on a patent application directed to BAC-based reverse genetics approaches to generate rSARS-CoV-2.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Chiem, K., Nogales, A., Almazán, F., Ye, C., Martínez-Sobrido, L. (2024). Bacterial Artificial Chromosome Reverse Genetics Approaches for SARS-CoV-2. In: Pérez, D.R. (eds) Reverse Genetics of RNA Viruses. Methods in Molecular Biology, vol 2733. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3533-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3533-9_9
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3532-2
Online ISBN: 978-1-0716-3533-9
eBook Packages: Springer Protocols